A review examines how myelin and oligodendrocyte dysfunction may contribute to ALS
Original source
Myelin and Oligodendrocyte Dysfunction in Demyelinating and Neurodegenerative Disorders: Signaling Pathways and Therapeutic Targets. (opens in a new tab)Compass summarised this from the study's abstract.
A narrative review discusses links between myelin-producing oligodendrocytes and amyotrophic lateral sclerosis (ALS), alongside multiple sclerosis and Alzheimer’s disease. It highlights signaling pathways involved in myelin formation and repair as possible therapeutic targets, while noting that the diseases have different underlying mechanisms.
Why this matters
The review may help researchers identify shared pathways for investigation in ALS. It does not provide evidence that targeting these pathways improves ALS or change treatment for people living with the disease.
Limitations and context
This is a narrative literature review, not a clinical trial or new patient study. The source does not establish that the proposed pathways or listed drugs improve ALS outcomes, and further disease-specific research would be needed.